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Histamine is a major mediator of allergic in-
fl  ammation (1). This role is supported by sev-
eral types of evidence, including release of 
histamine from cells participating in allergic 
  responses, reproduction of features of allergic 
infl  ammation by injected or inhaled histamine, 
reduction of allergic infl  ammation by histamine 
receptor antagonists, and more recently by 
demonstration that mice genetically modifi  ed 
to make less histamine have diminished capac-
ity to develop allergic infl  ammation (2). Cells 
of diverse function produce histamine. Tradi-
tional major sources are mast cells and baso-
phils, which store histamine in secretory 
granules, but other leukocytes (3), including 
platelets (4), have some capacity to produce 
histamine, as do enterochromaffi   n-like gastric 
cells and certain neurons. Foods also contain 
histamine, occasionally in amounts suffi   cient 
to cause histamine poisoning, which resembles 
conventional anaphylaxis (5). Whatever the bi-
ological source, histamine is thought to derive 
principally from metabolism of the ubiquitous 
amino acid histidine.
In asthma and other types of allergic infl  am-
mation, mast cells and basophils are the  postulated 
major sources of histamine, which is secreted in 
response to engagement of allergens with  surface-
bound IgE. Interestingly, most exacerbations of 
asthma requiring emergency room visits or hos-
pitalization seem to be associated with acute bac-
terial and viral infection of the respiratory tract 
rather than exposure to allergens themselves. 
Prominent among off  ending bacteria are myco-
plasmas (6), which also are linked to fi  rst onset 
of asthma and to chronic persistent asthma in 
humans (7–9) and in rodent models of allergic 
airway infl  ammation (10, 11).
These considerations led us to hypothesize 
that mast cells are the main source of respiratory 
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Mycoplasmas cause chronic infl  ammation and are implicated in asthma. Mast cells defend 
against mycoplasma infection and worsen allergic infl  ammation, which is mediated partly 
by histamine. To address the hypothesis that mycoplasma provokes histamine release, we 
exposed mice to Mycoplasma pulmonis, comparing responses in wild-type and mast cell–
defi  cient KitW-sh/KitW-sh (W-sh) mice. Low histamine levels in uninfected W-sh mice con-
fi  rmed the conventional wisdom that mast cells are principal sources of airway and serum 
histamine. Although mycoplasma did not release histamine acutely in wild-type airways, 
levels rose up to 50-fold above baseline 1 week after infection in mice heavily burdened 
with neutrophils. Surprisingly, histamine levels also rose profoundly in infected W-sh lungs, 
increasing in parallel with neutrophils and declining with neutrophil depletion. Further-
more, neutrophils from infected airway were highly enriched in histamine compared with 
naive neutrophils. In vitro, mycoplasma directly stimulated histamine production by naive 
neutrophils and strongly upregulated mRNA encoding histidine decarboxylase, the rate-
limiting enzyme in histamine synthesis. In vivo, treatment with antihistamines pyrilamine or 
cimetidine decreased lung weight and severity of pneumonia and tracheobronchitis in 
infected W-sh mice. These fi  ndings suggest that neutrophils, provoked by mycoplasma, 
greatly expand their capacity to synthesize histamine, thereby contributing to lung and 
airway infl  ammation.
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tract histamine and that mycoplasma infections of the respira-
tory tract provoke local histamine release, thereby contrib-
uting to allergic and infectious infl  ammation. To test these 
hypotheses, the studies described here used mast cell–defi  cient 
KitW-sh/KitW-sh (W-sh) mice to explore sources and release of 
histamine in acute and chronic respiratory tract  mycoplasmosis. 
These mice are profoundly mast cell defi  cient but have 
  normal levels of circulating basophils and other leukocytes 
(12, 13). Their mast cell defi  cit stems from impaired mast cell 
expression of c-kit (14), which is essential for mast cell dif-
ferentiation and survival. In some W-sh tissues (not including 
large airway), mast cell defi  ciency can be repaired by intra-
venous adoptive transfer of bone marrow–derived mast cells 
(BMMCs) in vitro diff  erentiated from wild-type C57BL/6 
(+/+) mice (12).
The infectious agent used in these studies is Mycoplasma 
pulmonis, a natural respiratory pathogen of rodents. Like other 
mycoplasmas, M. pulmonis lacks a cell wall and has a small ge-
nome (15). In immunocompetent hosts, M. pulmonis is mainly 
an extracellular bacterium that remains limited to the respira-
tory tract and exhibits an intriguing and incompletely under-
stood capacity to persist in the presence of pathogen-specifi  c 
antibodies (16). Exposure of a mycoplasma-naive mouse to 
M. pulmonis produces acute tracheobronchitis (and  pneumonia 
with higher level exposures), which subsides to persistent, 
low-level airway infl  ammation (17). Its presence is associated 
Figure 1.  Mycoplasma does not induce acute release of mast cell 
histamine. (A) Histamine levels in BAL supernatants were determined 2 h 
after airway infection with M. pulmonis in +/+ and mast cell–defi  cient 
W-sh mice and in W-sh mice with a super-normal population of intrapul-
monary mast cells established by adoptive transfer of +/+ BMMCs. “Not 
infected” mice were sham infected with sterile broth. Data are mean 
± SE; n = 3–6 animals per group; **, P < 0.01 in comparison with +/+ 
groups. There were no signifi  cant differences between infected and sham-
infected results in a given type of mouse. (B) Release of histamine and the 
secretory granule marker, β-hexosaminidase, was measured in BMMCs. 
Cells were exposed to serum from mice with high titers of M. pulmonis–
specifi  c Ig (immune serum), to serum from mice never exposed to myco-
plasma (naive serum), and to live M. pulmonis in combinations as shown. 
Control cells were incubated in Tyrode’s buffer. Data are mean ± SE; n = 3. 
There were no signifi  cant differences between groups.
Figure 2.  BAL histamine correlates with PMN levels. BAL histamine 
(A) and total PMNs (B) were determined up to 7 d after infection in W-sh 
and +/+ mice and compared with results in sham-infected mice. Closed 
diamonds, open diamonds, closed triangles, and open triangles represent 
data from W-sh–infected, W-sh sham-infected, +/+ infected and +/+ 
sham-infected mice, respectively. Data are mean ± SE; n = 3–6 animals 
per group; *, P < 0.05 in comparison with sham-infected W-sh values at 
all time points. In C, concentration of BAL histamine is plotted against 
total PMNs. Each data point derives from a single BAL sample in a single 
W-sh (left) or +/+ (right) mouse. In the W-sh panel, open circles and 
squares depict samples from mice 4 and 7 d, respectively, after sham 
  infection. Closed circles and squares represent samples from mice 4 and 
7 d, respectively, after infection with 0.5 × 106 CFU of M. pulmonis. In the 
+/+ panel, open squares represent samples obtained 7 d after sham 
infection. Closed triangles, circles, and squares represent samples ob-
tained 7 d after infection with 0.5 × 106, 1.0 × 106, and 2.0 × 106 CFU, 
respectively, of M. pulmonis. Dotted lines depict approximate baseline 
histamine concentrations. The intersection of the solid and dotted line 
identifi  es the approximate threshold number of BAL neutrophils in 
an infected mouse needed to generate a detectable rise in histamine 
above baseline.JEM VOL. 203, December 25, 2006  2909
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with sustained remodeling of airway epithelium and blood 
and lymphatic vessels (18) and long-lasting potentiation of 
neurogenic respiratory infl  ammation (19). Consequences of 
respiratory tract exposure to M. pulmonis are worse in mast 
cell–defi  cient mice than in wild-type mice because mast cell–
defi  cient mice develop a more severe, neutrophilic infl  am-
matory response, which persists rather than subsides in the 
fi  rst few weeks after infection (17).
RESULTS
Mast cells are the main source of baseline airway, lung, 
and serum histamine
As shown in Fig. 1 A and Fig. 2, histamine was consistently 
very low or undetectable in bronchoalveolar lavage (BAL) 
fl   uid from mast cell–defi  cient  W-sh mice not exposed to 
mycoplasma. This was also true of histamine in lung ho-
mogenates and serum of uninfected W-sh mice, as shown 
in Fig. 3 A. Given that W-sh mice have normal numbers of 
basophils (13), which also contain histamine, these fi  ndings 
suggest that mast cells are the principal source of histamine 
in the airway lumen, lung tissue, and serum of healthy mice. 
The magnitude of the contribution varied, with these data 
suggesting that mast cells contribute 99, 65, and 89% of air-
way lumen, lung tissue, and serum histamine, respectively, in 
+/+ animals. Adoptive transfer of +/+ BMMCs into W-sh 
mice did not increase levels of BAL histamine (Fig. 1 A), de-
spite the fact that lung parenchymal mast cell and histamine 
content were higher than in +/+ mice (unpublished data). 
In this regard it may be important that adoptive transfer of 
BMMCs does not restore mast cell populations to the larger 
airways and trachea, which could be a source of BAL hista-
mine in healthy +/+ mice. Alternatively, most histamine 
in epithelial lining fl  uid under baseline conditions may fi  lter 
from serum.
Mycoplasma does not induce acute histamine release 
into the airway lumen
As shown in Figs. 1 A and Fig. 2, M. pulmonis did not in-
crease the concentration of BAL histamine between 2 h and 
4 d after infection. Although BAL histamine levels were 
somewhat higher at 2 h than at later times, there was no dif-
ference in this regard between mice undergoing sham versus 
M. pulmonis infection; therefore, these diff  erences are not at-
tributable to infection. Furthermore, Fig. 1 A reveals that the 
W-sh mice “stocked” with adoptively transferred BMMCs to 
super-normal levels still do not react acutely to the introduc-
tion of mycoplasma into the airways, providing additional 
evidence that mast cells do not release histamine in response 
to M. pulmonis in vivo.
Mycoplasma does not release histamine from cultured 
mast cells
Fig. 1 B reveals that BMMCs do not respond directly to 
M. pulmonis by releasing histamine or the granule marker 
β-hexosaminidase. They also do not respond to the combi-
nation of mycoplasma and immune serum, which contains 
mycoplasma-specifi  c IgM, IgG, and IgA but not IgE (17). 
Positive control experiments revealed that Ca2+ ionophore 
A23187 (3 μM) released 28 ± 2% of β-hexosaminidase. 
Total histamine content of BMMCs was 0.636 ± 0.016 
μg/106 cells.
Mycoplasma increases BAL and lung histamine in mast 
cell–defi  cient mice with tracheobronchitis and pneumonia
Fig. 2 A reveals a large increase in BAL histamine 7 d after 
M. pulmonis infection in W-sh mice. This increase matched 
or exceeded the level in infected +/+ mice and was 125 
times higher than the level in sham-infected W-sh mice. 
Figure 3.  Increases in lung and serum histamine levels in 
mycoplasma-infected W-sh mice are not caused by induction of 
mast cells. (A) The top graph compares histamine concentrations in 
lung homogenates of uninfected +/+ and mast cell–defi  cient W-sh mice 
with those in the same types of mice 7 and 14 d after infection with 
M. pulmonis. The bottom graph compares levels of serum histamine in the 
same groups of mice. Data are mean ± SE; n = 4–6 animals per group; 
*, P < 0.05 in comparison with +/+ mice infected 14 d; **, P < 0.01 
in comparison with +/+ mice not infected; #, P = 0.05 in comparison 
with W-sh mice not infected. (B) These representative micrographs 
compare toluidine blue–stained lung and airway sections in sham- and 
mycoplasma-infected +/+ and W-sh mice. Arrows indicate some of the 
metachromatically staining mast cells in +/+ sections. Bar, 135 μM.2910  MYCOPLASMA INDUCES NEUTROPHILS TO PRODUCE HISTAMINE | Xu et al.
Fig. 2 B reveals that the increase in BAL histamine in in-
fected W-sh mice parallels an increase in BAL polymorpho-
nuclear neutrophils (PMNs), suggesting PMNs as a potential 
source of the histamine. Fig. 2 C confi  rms this suggestion by 
showing close correlation between histamine concentration 
and neutrophil number in paired samples of BAL. This cor-
relation is seen in +/+ and W-sh samples, with BAL hista-
mine rising to 50-fold above baseline in +/+ specimens, 
despite higher baseline concentrations of BAL histamine in 
+/+ versus W-sh samples. The threshold number of BAL 
PMNs for producing a detectable rise in histamine above 
baseline was between 105 and 106 cells. As shown in Fig. 3, 
histamine content also rose in lung tissue extracts 7 d after 
infection and further increased at 14 d. Thus, mycoplasma 
greatly increased the concentration of free histamine in the 
airway lumen and total histamine in lung extracts at later 
time points. These increases were associated with tracheo-
bronchitis and pneumonia in infected W-sh mice, as seen in 
Fig. 3 B and see Fig. 5 A.
Mycoplasma increases serum histamine in W-sh mice
As shown in Fig. 3 A, serum histamine concentrations in un-
infected and infected W-sh mice were low compared with all 
groups of +/+ mice. However, there was a twofold increase 
in histamine level 14 d after infection in W-sh mice, suggest-
ing that the more dramatic rise in lung histamine content in-
fl  uenced serum concentrations. The disparity between lung 
and serum in the extent of the rise suggests that the increase 
in lung histamine was largely local and not caused by a sys-
temic rise in histamine production.
Depleting PMN in infected W-sh mice decreases 
BAL histamine
As revealed by the data in Fig. 4, treatment of mycoplasma-
infected W-sh mice with anti–Gr-1 decreased BAL PMN and 
histamine content by  88 and 79%, respectively. These pro-
portionate drops are consistent with PMNs being the major 
source of histamine in infected animals.
Lung infl  ammation and airway remodeling are severe 
and persistent in infected W-sh mice
As shown in Fig. 3 B and Fig. 5 A, M. pulmonis–infected 
W-sh mice developed severe and progressive tracheobronchi-
tis and pneumonia. In contrast, infected +/+ mice devel-
oped mild and transient lung and airway infl  ammation, which 
mostly resolved by 7 d after infection. Infl  ammatory cells 
in the lumen and alveoli were almost exclusively PMN. The 
chronic infl  ammatory process in W-sh mice was accompa-
nied by progressive airway remodeling as refl  ected by gob-
let  cell hyperplasia (quantitated in Fig. 5 B). In contrast, 
goblet cell hyperplasia in +/+ mice was milder and more 
ephemeral. Control mice did not develop infl  ammation or 
remodeling between 2 and 28 d after sham infection. There 
were no signifi  cant diff  erences in goblet cell hyperplasia in 
mice treated with the histamine H1 receptor antagonist pyril-
amine or the H2 antagonist cimetidine singly or in combina-
tion, compared with responses in mice treated with saline 
(unpublished data).
Figure 4.  Anti-PMN antibodies decrease BAL PMNs and histamine 
levels proportionately in mycoplasma-infected, mast cell–defi  cient 
mice. W-sh mice were injected with control (Isotype) or PMN-directed 
anti–GR-1 mAb 5 d after infection with M. pulmonis (M.p.). Levels of 
PMN and histamine in BAL were determined 2 d after mAb injection. 
“Uninfected” mice were sham-infected. Data are mean ± SE; n = 3–4 
animals per group; *, P < 0.05 and **, P < 0.01 compared with isotype 
control groups.
Figure 5.  Neutrophilic tracheobronchitis is associated with air-
way epithelial remodeling in mycoplasma-infected mice. (A) These 
representative micrographs of periodic acid–Schiff and hematoxylin-
stained airway sections compare histopathology in +/+ and W-sh mice 
Bar, 180 μM. Infected W-sh mice developed more severe and persistent 
neutrophilic infl  ammation accompanied by goblet cell hyperplasia, as 
refl  ected by increased numbers of periodic acid–Schiff–positive airway 
epithelial cells (arrows). Control mice were sham infected with saline 
7 d before harvest. (B) Airway goblet cell numbers were quantitated in 
tissue sections from mycoplasma- and sham-infected mice. Symbols 
represent the following: closed diamonds, mycoplasma-infected W-sh; 
closed triangles, mycoplasma-infected +/+; open diamonds, sham-
infected W-sh; open triangles, sham-infected +/+. Data are mean ± SE; 
n = 4–5 animals per group; *, P < 0.05 and **, P < 0.01 compared 
with infected +/+.JEM VOL. 203, December 25, 2006  2911
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Mast cells and basophils are not sources of mycoplasma-
induced increases in histamine in W-sh mice
As shown in Fig. 3 B, mast cells were present in airway walls 
of +/+ mice, with and without infection. However, no mast 
cells were noted in W-sh mice in the presence or absence of 
infection, bronchitis, and pneumonia. These fi  ndings suggest 
that local mast cell hyperplasia in infected W-sh mice does not 
explain the observed rise in airway and lung histamine. As 
noted above, W-sh mice injected with BMMCs developed 
mast cell hyperplasia in lung parenchyma but did not develop 
mast cells in large airway walls. This fi  nding indicates that our 
histochemical approaches can detect mast cells in lungs of 
W-sh mice when they are present. As shown by fl  ow cytometry 
data in Fig. 6 A, lungs of uninfected and infected W-sh and 
+/+ mice contained small but distinct populations of 
CD131+/IgE+/c-kitlo cells with surface marker and morphol-
ogy consistent with basophils. These populations separated 
cleanly from the PMNs predominating in lungs of infected 
W-sh mice. Similar results were obtained when FcεRIα was 
used as a marker instead of CD131 (unpublished data). As re-
vealed in Fig. 6 B, the absolute number of basophils was sig-
nifi  cantly lower in W-sh mice 7 and 14 d after infection than 
in sham-infected mice. Therefore, changes in basophil num-
bers do not explain the observed increases in lung histamine.
Mycoplasma induces PMN histamine production and release
As seen in Fig. 7 and Fig. 8 A, direct exposure of purifi  ed, 
BM-derived, mycoplasma-naive PMNs to M. pulmonis dra-
matically increased total histamine content compared with 
cells not exposed to mycoplasma. This eff  ect of mycoplasma 
was dose responsive and was observed with live or heat-killed 
organisms, although response to the latter is muted compared 
with the response to live organisms. There was no diff  erence 
in the extent of increase in PMNs from W-sh and +/+ mice 
(9.1- and 10.3-fold, respectively). Levels of histamine similar 
to those in mycoplasma-exposed naive BM PMNs were ob-
served in purifi  ed, lung BAL-obtained PMNs natively ex-
posed to M. pulmonis in infected W-sh and +/+ mice. 
Histamine content of BAL PMNs was measured 1 and 7 d 
after infection in W-sh mice but on day 1 only in +/+ mice 
(in which infl  ammation had subsided by day 7 to the point 
that few PMNs could be retrieved by BAL). There were 
no signifi  cant diff  erences in histamine levels in W-sh mice 
on day 1 versus 7. Mycoplasma itself was not a source of 
  histamine. Fig. 8 B also demonstrates that mycoplasma stimu-
lates histamine release from naive PMNs. Preparations of BM 
and lung PMNs in these experiments were at least 98% pure, 
with no observed contamination with mast cells, basophils, 
or eosinophils. These data suggest that PMNs are a source of 
Figure 6.  Flow cytometry reveals that changes in basophil num-
bers do not account for increases in histamine in mycoplasma-
infected mice. (A) These representative plots compare surface expression 
of CD131 (β chain common to receptors for IL-3, IL-5, and GM-CSF), IgE, 
and c-kit in lung cells from +/+ and W-sh mice. These data are from 
mice studied 14 d after sham or mycoplasma infection. The percentage of 
cells in specifi  c gates (boxed) is indicated. Basophils are CD131 and IgE 
positive but express little or no c-kit, distinguishing them from mast cells. 
In lungs from all types of mice, the CD131+/IgE+ subset (gated as noted) 
was a small but distinct population of extractable cells, consisting almost 
entirely of c-kit− and c-kitlo cells. As shown in the lower right panel inset, 
these cells feature basophilic granules with segmented nuclei. (B) The 
number of basophils per lung 7 and 14 d after infection was calculated 
by multiplying total cells by the fraction of CD131+/IgE+ cells. Data are 
mean ± SE; n = 3 animals per group; *, P < 0.05 in comparison with 
uninfected W-sh.2912  MYCOPLASMA INDUCES NEUTROPHILS TO PRODUCE HISTAMINE | Xu et al.
histamine, that mycoplasma exposure strongly enhances his-
tamine production and release, and that PMNs do not diff  er 
strongly in these respects in W-sh and +/+ mice.
Mycoplasma increases PMN transcripts encoding 
histidine decarboxylase
As shown in Fig. 6 C, M. pulmonis strongly augmented levels of 
histidine decarboxylase (HDC) mRNA in naive, BM-derived 
PMNs. PMNs retrieved from infected animals by BAL had 
high levels of HDC relative to levels in naive cells. These 
fi  ndings suggest that increased expression of HDC accounts 
for increased histamine production by PMNs in mycoplasma-
infected mice. As in the histamine measurements, HDC 
mRNA content was measured on day 1 and 7 in PMNs from 
W-sh mice, without fi  nding a signifi  cant diff  erence between 
values at the two time points.
Antihistamines attenuate infl  ammation in infected 
W-sh mice
As shown in Fig. 9, treatment of W-sh mice with H1 or H2 
antihistamines (pyrilamine or cimetidine) decreased the ratio 
of lung to body weight, and also pneumonia severity, in or-
gans harvested 10 d after infection with mycoplasma com-
pared with results in control mice injected with saline. The 
ratio of lung to body weight rises in infi  ltrative lung diseases 
and in lung-selective edema. The change in lung to body 
weight ratio in response to antihistamine was more dramatic 
than the change in pneumonia grade, suggesting that part of 
Figure 7.  Histamine production and release is stimulated by live or 
dead mycoplasma and is dose sensitive. M. pulmonis (M.p.)–stimulated 
production of histamine was assessed in PMN purifi  ed from BM of +/+ 
and W-sh mice. PMNs and live or heat-killed mycoplasma were cocul-
tured for 200 min using PMN to M. pulmonis CFU ratios of 1:1 (gray bars), 
1:10 (hatched bars), and 1:100 (black bars), followed by measurement of 
total and released histamine. White bars show total and released hista-
mine in PMNs incubated alone, without mycoplasma. Data are mean 
± SE; n = 3; P < 0.001 for each 1:100 value versus PMN alone control 
values, for W-sh 1:10 live M. pulmonis versus PMN alone and versus 
W-sh 1:100, for +/+ 1:10 live M. pulmonis versus PMN alone and versus 
+/+ 1:100; P < 0.01 for total histamine W-sh dead M. pulmonis 1:100 
and 1:10 versus PMN alone, and for 1:10 versus 1:100.
Figure 8.  Mycoplasma increases PMN histamine production and 
HDC transcripts in vitro and in vivo. (A) Total histamine production 
was measured in BM PMNs purifi  ed from mycoplasma-naive +/+ and 
W-sh mice and incubated with live M. pulmonis in a ratio of 1 neutrophil 
per 10 CFU. Histamine content also was measured in mycoplasma alone 
and in PMN purifi  ed from M. pulmonis–infected lungs of +/+ and W-sh 
mice 1 and 7 d after infection, respectively. (B) Histamine released outside 
of the cell during incubation with mycoplasma was measured in PMN 
purifi  ed from mycoplasma-naive +/+ and W-sh mice. (C) Real time 
RT-PCR was used to measure expression of mRNA encoding HDC, the 
rate-limiting enzyme in endogenous production of histamine. Cell sources 
and conditions are as in A. Results are expressed relative to levels of 
mRNA encoding HPRT. Data are mean ± SE; n = 3–5 animals per group; 
*, P < 0.05, **, P < 0.01, and ****, P < 0.0001 compared with no myco-
plasma control.JEM VOL. 203, December 25, 2006  2913
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the antihistamine eff  ect on the ratio was caused by a decrease 
in lung edema. The combination of H1 and H2 antihista-
mine also attenuated these endpoints, although the diff  er-
ences were not signifi  cant. As also found in a prior study 
using the same level of exposure to M. pulmonis (17), several 
infected control animals (3 out of 8 in this study) died before 
scheduled lung harvest. On the other hand, there were no 
deaths (0 out of 8) in the cimetidine-treated group, and only 
1 out of 8 and 1 out of 6, respectively, in pyrilamine alone 
and cimetidine plus pyrilamine groups. Therefore, antihista-
mines may also protect from death from mycoplasma in 
this model.
DISCUSSION
In this study, exploring mycoplasma-induced infl  ammation 
in mast cell–defi  cient mice unmasked a previously underrec-
ognized contribution of PMNs to local production of hista-
mine. In the context of the hypotheses tested by these studies, 
some fi  ndings were contrary to expectation and others were 
entirely unanticipated, thereby yielding fresh insights regard-
ing the nature of infl  ammation in chronic tracheobronchitis 
and pneumonia. At the start of these studies, the main hy-
pothesis was that M. pulmonis (which is a common respiratory 
tract pathogen in wild populations of rodents) degranulates 
mast cells, thereby boosting local infl  ammation and linking 
infectious and allergic infl  ammation in the airway. Although 
we found no evidence of direct stimulation of mast cells by 
mycoplasma, our results show that there may indeed be a link 
between mycoplasma infection and allergic infl  ammation. 
However, this link is forged in part by direct, inducible ex-
pression and release of the classic allergic infl  ammatory medi-
ator, histamine, from an unexpected source, PMNs. Some 
implications of these fi  ndings are discussed further below.
Because of the focus on comparing sources of histamine 
in wild-type and selectively mast cell–defi  cient mice, these 
studies establish defi   nitively that mast cells are the chief 
source of lung and airway histamine at baseline, that is, in 
mice without respiratory tract infl  ammation. Although a 
mast cell origin for respiratory tract histamine will not sur-
prise many investigators, these fi  ndings for the fi  rst time re-
veal the extent of the contribution. Levels of free histamine 
in the airway lumen, as assessed by content in BAL superna-
tants from +/+ and W-sh mice, are almost entirely (99%) 
contributed by mast cells. Given that BAL histamine does 
not increase in mice after parenchymal lung mast cell popula-
tions are augmented by adoptive transfer of BMMCs, it is 
likely that much or most free airway histamine in healthy 
mice originates from blood or plasma, like many components 
of epithelial lining fl  uid. In turn, most plasma histamine likely 
was produced in multiple organs. When studied in vitro, 
mast cells from a variety of sources exhibit a baseline level of 
histamine release without specifi  c stimulation (20, 21), as also 
seen in our BMMC data in Fig. 1 B. This study’s compari-
sons of serum histamine levels in +/+ and W-sh mice sug-
gest that the vast majority of serum histamine is from mast 
cells, a possibility raised previously by studies of IgE-depen-
dent anaphylaxis in mast cell–defi  cient  KitW/KitW-v mice 
(22). The failure of BMMCs adoptively transferred to the 
lung to increase BAL histamine levels (as revealed by data in 
Fig. 1 A), despite a large increase in histamine content of 
whole lung extracts, is consistent with a plasma origin of 
most BAL histamine in healthy mice.
Our study does not support our original hypothesis that 
M. pulmonis degranulates mast cells acutely because live or-
ganisms did not aff  ect cultured mast cells and did not increase 
histamine levels in BAL at early time points after infection in 
vivo. However, it is possible that the baseline levels of hista-
mine prevented detection of acute, low-level release from 
mast cells. Unexpectedly, BAL and lung histamine levels rose pro-
gressively in W-sh mice at later time points, especially 1–2 wk 
after infection when levels came to equal or exceed those in 
+/+ mice. The histopathological analysis established that 
these increases were not caused by the appearance of mast 
cells in W-sh mice and coincided with progressive worsening 
of neutrophilic tracheobronchitis and pneumonia. Similarly, 
we cannot attribute the large increases in W-sh histamine to 
recruitment of basophils, which decreased in number as in-
fl  ammation progressed, as shown by FACS. Indeed, the prin-
cipal source of histamine appeared to be PMNs, which 
Figure 9.  Antihistamines attenuate pneumonia and lung to body 
weight ratio in mycoplasma-infected, mast cell–defi  cient mice. 
W-sh mice were treated daily with H1-selective antihistamine (pyrilamine), 
H2-selective antihistamine (cimetidine), both antihistamines in combina-
tion, or saline. Lungs harvested 10 d after infection and 7 d after starting 
antihistamine treatment were weighed and subjected to histopathological 
scoring for pneumonia (maximal possible score is 26). The top panel 
shows pneumonia grades in each group. The bottom panel shows ratio 
of lung weight (mg) to body weight (g). Data are mean ± SE; n = 5–8 
animals per group; *, P < 0.05 and ***, P < 0.001 compared with 
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populated the airway and alveolar lumen in large numbers, 
and which tracked well with the rise in histamine as revealed 
by comparing the panels in Fig. 2. As also noted in our prior 
work with this model (17), the severity of neutrophilic lung 
and airway infl  ammation was greater in W-sh than in +/+ 
mice. The diff  erence was especially large by 1 wk, when in-
fl  ammation in +/+ mice had substantially resolved but in 
W-sh mice continued to worsen.
The basis of the diff  erence in neutrophilic response be-
tween +/+ and W-sh mice is not clear. In part it may be be-
cause of the higher mycoplasma burden developing in W-sh 
mice in the fi  rst few days of infection. Later, when myco-
plasma burden becomes similar in both types of mice, greater 
neutrophilia in W-sh mice may be caused by loss of a suppres-
sive eff  ect of histamine on PMN infl  ux, as suggested by exag-
gerated PMN fl  ux into a skin pouch model of infl  ammation 
in mice lacking HDC (23). If this is the case, it is conceivable 
that if not for the production of histamine by PMN, the neu-
trophilia would be even more exaggerated in W-sh mice. 
Despite diff  erences  between  +/+ and W-sh mice in the 
magnitude of the neutrophilic response to a given dose or 
burden of M. pulmonis—and notwithstanding higher baseline 
BAL histamine levels in +/+ mice tending to mask the 
PMN contribution to histamine at lower levels of neutro-
philic infl   ammation—the present data (Fig. 2 C) establish 
that airway histamine levels rise markedly in +/+ mice when 
neutrophil numbers comparable to those seen in mice are 
provoked by larger initial inocula of mycoplasma. Thus, a 
major neutrophil contribution to airway histamine is not a 
phenomenon limited to mast cell–defi  cient mice. In this re-
gard, the lack of an intrinsic diff  erence between +/+ and 
W-sh mice in vivo is underscored by the absence of major 
diff  erences between naive PMN from W-sh and +/+ mice 
in mycoplasma-stimulated histamine synthesis and release 
in vitro. Greater histamine content in W-sh mice at the lower 
mycoplasma dose (0.5 × 106 CFU) was more likely caused 
by higher numbers of mycoplasma-stimulated PMNs than to 
intrinsic diff  erences in W-sh and +/+ neutrophil responsive-
ness to mycoplasma. Furthermore, the increase in local pro-
duction of histamine in W-sh mice infected for 2 wk was 
suffi   ciently great to increase histamine levels in serum. This 
independently supports the validity and importance of the 
increases in lung and airway histamine. The elevations of se-
rum histamine in W-sh mice, however, remained well below 
levels in +/+ animals, with or without infection, providing 
further evidence that extra-pulmonary sources (perhaps most 
notably mast cells in the skin) make the largest contribution 
to circulating levels of histamine in +/+ mice.
The marked increase in airway epithelial remodeling in 
infected W-sh mice versus infected +/+ mice, as refl  ected by 
goblet cell hyperplasia, also probably relates to more severe 
and persistent infection in W-sh mice (17). Unlike eff  ects of 
live mycoplasma on PMN production of HDC mRNA and 
histamine, eff  ects on epithelial remodeling probably were not 
caused by live mycoplasma and its products interacting alone 
with respiratory epithelium and goblet cell precursors. This is 
because epithelial remodeling, and mycoplasma-stimulated 
tracheal angiogenesis and lymphangiogenesis, occur only in 
the context of an infl  ammatory response and development of 
mycoplasma-specifi  c antibodies and immune complexes (16). 
Indeed, transfer of immune serum to B cell–defi  cient mice 
reconstitutes mycoplasma-induced remodeling (16). The 
higher burdens of bacterial antigen and higher titers of myco-
plasma-specifi  c antibodies in W-sh mice (17) presumably in-
crease the formation of antigen–antibody complexes and 
infl  ammation in the airway, thereby augmenting antibody-
dependent goblet cell hyperplasia.
These results provide the fi  rst evidence that mycoplasma 
stimulates PMN production of histamine. The signifi  cance of 
this novel fi  nding is not so much that PMNs and other leu-
kocytes can be sources of histamine, because past studies sug-
gested that BM-derived cells other than mast cells and 
basophils can produce small amounts of this mediator (3, 24, 
25). Rather, the signifi   cance lies in direct stimulation of 
PMNs by a common respiratory pathogen strongly inducing 
PMN production of histamine, and also in the unexpected 
magnitude of the eff  ect on histamine levels in airway lumen, 
lung tissues, and serum. The fi  nding of mycoplasma-induced 
increases in histamine content of PMNs purifi  ed from BM 
further argues that internalization of histamine from other 
sources is not a likely explanation of our fi  ndings.
Our data also allow a quantitative comparison of hista-
mine levels in PMNs versus mast cells. As shown in Fig. 7, 
highest expression of PMN histamine ( 10 pmol/106 cells = 
 1.1 ng/106 cells) was seen in PMNs purifi  ed from W-sh 
BM. Similar levels ( 6.4 pmol/106 cells =  0.70 ng/106 
cells) were seen in PMNs from infected lung, as shown in 
Fig. 8 A. On the other hand, unstimulated PMNs contained 
only  0.04 ng/106 cells. This compares to  0.64 μg of his-
tamine per 106 BMMCs. Based on these data, there is a 580–
910-fold diff   erence between the histamine content of 
BMMCs and mycoplasma-stimulated PMNs, compared with 
a 16,000-fold diff  erence between BMMCs and unstimulated 
PMNs. It is possible that the histamine content of BMMCs 
does not accurately refl  ect that of lung and airway mast cells. 
Nonetheless, the estimates of histamine content obtained by 
assaying purifi  ed PMNs from infected lung fi  t well with the 
hypothesis that PMNs are the major source of BAL histamine 
in the independent measurements shown in Fig. 2. Total 
histamine content of the 2.4 ml of BAL fl  uid from infected 
W-sh mice 7 d after infection was  16 ng compared with the 
 9 ng expected to lie within the observed  13 × 106 PMNs 
(based on  0.7 ng/106 cells observed in PMNs purifi  ed from 
infected lungs), with the diff   erence being accounted for 
mainly by extracellular, secreted histamine. Thus, in healthy 
uninfl  amed lung, which contains resident mast cells but very 
few PMNs or basophils, mast cells are by far the major source 
of extracellular and stored histamine. This conclusion re-
ceives strong support from Fig. 1, which shows data obtained 
very early after infection, before major neutrophilic infl  am-
mation has had an opportunity to develop. However, in the 
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and pneumonia, the number of PMNs relative to mast cells 
becomes so great (easily a several thousandfold diff  erence in 
the airway lumen) that PMN production of histamine, aug-
mented by exposure to bacteria, is substantial, even surpass-
ing the mast cell contribution. This previously unsuspected 
capability of PMNs was uncovered fortuitously by examining 
the phenomenon in mast cell–defi  cient mice. Thus, PMNs 
become a major source of airway histamine by two principal 
mechanisms: (a) ramping up histamine production in each 
cell in response to bacteria, and (b) increasing their numbers 
to achieve overwhelming numerical superiority over other 
histamine-producing cells.
The fi  nding that indices of tracheobronchitis and pneu-
monia in mast cell–defi  cient mice are diminished by treatment 
with pyrilamine or cimetidine suggests that neutrophil-derived 
histamine is proinfl  ammatory in this model. The magnitude 
of this eff  ect may be underestimated, because more mice died 
in the untreated control group before lung harvest than in 
antihistamine-treated groups, thereby precluding assessment 
of infl  ammation in the sickest mice. This eff  ect may have 
prevented the observed reduction in indices of lung infl  am-
mation from achieving statistical signifi  cance in the group 
treated with the combination of pyrilamine and cimetidine. 
In any case, further investigations are needed to determine 
whether these observations in mycoplasma-infected mice 
  apply to other microbes and other mammals. If human PMNs 
respond similarly, the histamine produced could contribute 
to worsening of allergic symptoms in acute respiratory infec-
tions, which are associated with PMN infl  ux into the airways 
and with most exacerbations of asthma severe enough to re-
quire emergency treatment or hospitalization (26–29). These 
fi  ndings also suggest a mechanism for some of the infl  amma-
tion and bronchoconstriction in chronic purulent respiratory 
tract infections and noninfectious neutrophilic infl  ammation, 
as in cystic fi  brosis (30, 31) and chronic, cigarette-associated 
bronchitis (32).
Finally, our studies suggest that the mechanism of the in-
crease in histamine production by naive PMNs in vitro 
involves induction of transcription of the gene encoding the 
rate-limiting enzyme in endogenous synthesis, HDC. Similar 
elevations of HDC transcript levels were found in PMNs 
purifi  ed from airways of infected mice. Thus, this mecha-
nism for stimulated histamine production appears to apply 
in vivo and in vitro. Furthermore, the magnitude of the in-
crease in HDC mRNA parallels that of the increase in hista-
mine production. Thus, the mechanism of the mycoplasma 
eff  ect on PMNs is likely to involve increased production of 
HDC, rather than an alternative mechanism, such as slower 
rates of histamine degradation. This conclusion is consistent 
with studies suggesting that leukocytes infi  ltrating foci of 
allergic infl  am mation express HDC transcripts by in situ 
mRNA hybridization and also contribute to increased HDC 
activity (25). Further studies will be required to establish the 
nature of the signals passed between mycoplasma and PMN, 
and to dissect intracellular pathways leading to an increase in 
HDC transcription.
In conclusion, this study shows that PMNs can become a 
major source of histamine in airway mycoplasma infection, 
which increases histamine production by up-regulating  transcripts 
encoding the rate-limiting enzyme in histamine production. 
Thus, histamine is a mediator shared by allergic and infectious 
varieties of airway infl  ammation.
MATERIALS AND METHODS
Animals. Mast cell–defi  cient C57BL/6 W-sh mice were provided originally 
by Peter Besmer (Memorial Sloan-Kettering Institute, New York, NY). 
Wild-type C57BL/6 Kit+/Kit+ (+/+) mice were purchased from Charles 
River. Mice were housed under specifi  c pathogen-free barrier conditions as 
described (12, 17) and were infected at 8–10 wk of age, except in experiments 
involving mast cell–reconstituted and control animals for which 18-wk-old 
mice were used. The University of California at San Francisco Institutional 
Animal Care and Use Committee approved all experimental procedures.
Mycoplasma infection, PMN depletion, and BAL. For most experi-
ments, W-sh or +/+ mice were anesthetized intramuscularly with ketamine 
and xylazine and infected intranasally with 5 × 105 CFU of M. pulmonis 
strain UAB CT7 (25 μl in each nostril) as described (17). For certain other 
experiments, +/+ mice were infected with higher doses of mycoplasma 
(1.0 × 106 or 2.0 × 106 CFU). Serum was obtained from animals before 
sacrifi  ce. Selective neutropenia was induced by i.p. injection of 250 μg of 
anti–Gr-1 RB6-8C5 mAb (BD Biosciences) 5 d after infection. Control 
mice received no mAb or were injected with rat IgG2b κ isotype control 
mAb (A95-1; BD Biosciences). Mice were killed 2 d after mAb injection. 
To obtain samples of airway epithelial lining cells and fl  uid, a 22-gauge cath-
eter was inserted into exposed tracheal lumen. BAL samples were collected 
in three 0.8-ml PBS washes per mouse. Supernatants were stored at –80°C 
until use. Cell pellets were collected for PMN purifi  cation or fl  ow cytometry 
as described below.
Tissue mast cell and goblet cell staining. After sacrifi  ce, lungs were ex-
cised, immersed in 4% paraformaldehyde, and fi  xed overnight. Specimens 
were embedded in paraffi   n and cut into 5-μm sections. Deparaffi   nized sec-
tions were stained with hematoxylin and eosin for general observation or 
with 0.5% acidifi  ed toluidine blue or periodic acid–Schiff   reagent to identify 
mast and goblet cells, respectively. All goblet cells in each section were 
counted. To assess eff  ects of histamine receptor antagonists on mycoplasma-
induced goblet cell hyperplasia, mice were injected i.p. with 20 mg/kg of 
pyrilamine (H1 antagonist), 40 mg/kg of cimetidine (H2 antagonist), or sa-
line (control) daily for 7 d, starting 30 min before infection of +/+ mice 
with 0.5 × 106 M. pulmonis.
Mast cell culture and degranulation assays. Cells from femoral BM of 
5–7-wk-old +/+ mice were cultured in IL-3–containing medium as de-
scribed (12) for 4–8 wk to generate BMMCs of >95% purity as assessed by 
the presence of metachromatic granules in toluidine blue–stained cells. 
BMMCs (105/well) were incubated at 37°C for 2.5 h or overnight with 1:5 
dilutions of serum from mycoplasma-naive mice or from infected +/+ mice 
24 d after infection, when high titers of M. pulmonis–specifi  c Ig have devel-
oped (17). After incubation, cells were washed in cold Ca2+- and Mg2+-free 
Tyrode’s buff  er and then incubated with 106 CFU of M. pulmonis at 37°C for 
1 h in Tyrode’s buff  er containing Ca2+ and Mg2+. Cell supernatants and 
pellets were collected. Pellets were resuspended, washed three times, and 
sonicated. Samples were stored at –80°C before hexosaminidase and hista-
mine assays. Incubation of BMMCs with ionophore A23187 (3 μM) was 
used as a positive control for degranulation. Cell viability was assessed by ex-
clusion of vital dye (trypan blue).
Purifi  cation of BAL and BM-derived PMNs and exposure to myco-
plasma. PMNs from BAL and BM were isolated and purifi  ed from W-sh 
and +/+ mice as described (33). Purity was established by fl  ow cytometry 
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after cytostaining with Diff  -quik (American Scientifi  c Products). Purifi  ed 
BAL PMNs were suspended (107 cells/ml), sonicated, and frozen for later 
assays of HDC mRNA and histamine content (see below). Naive BM 
PMNs were assessed for histamine production and release in a 96-well plate 
assay. Cells were incubated at 37°C for 200 min at a density of 2.5 × 106 or 
107 cells/ml with PBS or live M. pulmonis (10 CFU per neutrophil). Dose–
response experiments were performed with PMN to M. pulmonis ratios 
ranging from 1:0 to 1:100, using live or heat-killed (65°C, 30 min) organisms. 
Cells were centrifuged after incubation. Supernatants were collected. Pellets 
were washed three times, collected, and sonicated. All samples were stored 
at –80°C until use.
Measurement of HDC mRNA. Total RNA from M. pulmonis–  stimulated 
PMN purifi  ed from mycoplasma-naive BM or from BAL of infected 
mice was prepared using Qiagen RNeasy kits and incubated with DNase 
(Promega) to remove residual genomic DNA. Expression of mRNA was 
quantifi  ed by real time RT-PCR. Primer probe sets were purchased from 
MWG Biotech. Oligonucleotide sequences and expected amplimer length 
were as follows: HDC (primers 5′-T  G  A  G  G  A  A  G  A  C  A  A  G  C  A  A  C  A  G  G  -3′ 
and 5′-G  C  C  T  G  T  C  A  A  A  T  G  C  A  C  A  G  A  C  T  -3′; probe 5′-C  G  T  T  G  C  A  C  A  G-
A  C  A  A  A  C  A  C  A  G  G  C  A  -3′ with 5′ carboxyfl  uorescein and 3′ black hole 
quencher-1; amplimer 83 bp); endogenous control hypoxanthine guanine 
phosphoribosyl transferase (HPRT) (primers 5′-A  G  G  T  T  G  C  A  A  G  C  T  T  G-
C  T  G  G  T  -3′ and 5′-T  G  A  A  G  T  A  C  T  C  A  T  T  A  T  A  G  T  C  A  A  G  G  G  C  A  -3′; probe 
5′-T  G  T  T  G  G  A  T  A  C  A  G  G  C  C  A  G  A  C  T  TTGTTGGAT-3′ with 5′ 6-carboxy-
2’, 4, 4’, 5′, 7, 7’-hexachlorofl  uorescein; amplimer 123 bp). Both amplifi  ca-
tions were performed simultaneously for 40 cycles of 95°C for 15 s and 60°C 
for 15 s on a Chromo 4 PTC-200 thermal cycler (MJ Research; Bio-Rad 
Laboratories) using Superscript III Platinum RT-PCR kits (Invitrogen). 
  Results were expressed as cycle threshold (Ct) values and quantitated by a 
comparative approach. Diff  erences between naive and mycoplasma-exposed 
samples were expressed as fold change of HDC Ct relative to HPRT Ct 
in each sample using the formula 2-∆∆Ct, where ∆Ct = C tHDC – CtHPRT 
and −∆∆Ct = ∆CtMycoplasma – ∆CtNaive. Real-time PCR data from one prepa-
ration of mycoplasma-naive PMNs was chosen arbitrarily as a control for in-
terassay (plate-to-plate) variation. The observed ratio of HDC Ct to HPRT 
Ct of this sample was assigned a value of 1 for each multiwell plate and used 
to normalize the test data from other samples in each plate.
Measurement of 𝗃-hexosaminidase and histamine. Release of β-hex-
osaminidase from BMMCs was measured spectrophotometrically using 
p-nitrophenyl-N-acetyl-β-d-glucosaminide (Sigma-Aldrich) as described (34). 
Histamine concentrations in lung homogenates, BAL, BMMCs, and PMNs 
were determined by Immunotech ELISA (Beckman Coulter).
Flow cytometry. Antibodies were purchased from BD Biosciences unless 
otherwise indicated. For studies on cells obtained by BAL, the following an-
tibodies were used: FITC or PE-conjugated Mac-1 and FITC-conjugated 
Gr-1; PE-conjugated CD3, PE-conjugated F4/80, TC-conjugated CD4, 
CD8, and B220 (Caltag Laboratories); rat anti–mouse monoclonal antibody 
CD16/32 was used to block nonspecifi  c binding. Cells were analyzed by 
FACSCaliber fl  ow cytometer (BD Biosciences). Cells double-positive for 
Mac-1 and Gr-1 were considered to be PMNs. To estimate PMN number 
in mice treated with anti–GR-1, forward and side scatter characteristics also 
were used. To obtain tissue cells for analysis by fl  ow cytometry, lungs were 
perfused via cardiac ventricles with 10 ml of cold PBS, cut into small pieces, 
and minced through a 70-μm strainer (BD Biosciences Discovery Labware) 
as described (35). Resulting cells were washed with PBS/2% FCS. Resus-
pended cell pellets were incubated for 10 min with anti-CD16/CD32 before 
adding the appropriate antibody combinations. Cells were stained with 
APC-Alexa Fluor 750 anti-CD4 (Caltag Laboratories), APC anti–c-kit, 
PE anti-CD131, biotin anti-FcεRIα, biotin anti-IgE, PE anti-FcεRIα 
(eBioscience), and streptavidin PerCP-Cy5.5. Exclusion of 4’, 6-diamidino-
2-phenylindole (Roche Applied Science) was used to assess cell viability. 
Samples were analyzed on a LSR II fl  ow cytometer (BD Biosciences).
Adoptive transfer of mast cells into mast cell–defi  cient  mice. In 
vitro–diff  erentiated 5–6-wk-old BMMCs were injected i.v. into 5-wk-old 
W-sh mice (107 cells/mouse). Mice were used in experiments 12 wk after 
adoptive transfer, by which time mice establish large populations of mast 
cells in the lung parenchyma and small airways (12).
Grading eff  ects of antihistamines on pneumonia. W-sh mice infected 
intranasally with M. pulmonis (5 × 105 CFU) were injected i.p. with 40 mg/kg 
pyrilamine (H1-selective antihistamine), 60 mg/kg cimetidine (H2-selective 
antihistamine), both drugs, or saline. Drugs were given daily from day 3 after 
infection until day 10, when lungs were harvested, weighed, and subjected to 
histopathological grading of pneumonia severity as described (17).
Statistical analysis. Results are expressed as the mean ± SE. Data were 
compared by t test with P < 0.05 considered signifi  cant.
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